DYADIC INTERNATIONAL INC 8K

Dyadic International, Inc. announced its 2025 financial results, highlighted a deeper shift toward commercialized animal-free protein products and partnerships, and provided updates on multiple collaborations and grant-funded programs, alongside a modestly lower cash balance and increased net loss.

Dyadic International, Inc. reported its financial results for the year ended December 31, 2025 and highlighted a series of commercialization and partnership milestones as it transitions to a more commercially driven business. The company recorded 2025 revenue of $3.09 million (down from $3.50 million in 2024), a higher net loss of $7.36 million (vs. $5.81 million in 2024), and year-end cash, cash equivalents, restricted cash and investment-grade securities of approximately $8.6 million. Operationally, Dyadic saw the commercial launch of AlbuFree DX recombinant human albumin by Proliant Health & Biologicals, launched recombinant DNase I (RNase-free) with Fermbox Bio, entered an OEM distribution agreement with IBT Bioservices, and signed a development and commercialization agreement with BRIG Bio for animal-free bovine alpha-lactalbumin, while its partner Inzymes plans to commercialize recombinant non-animal bovine chymosin in 2026. The company also expanded collaborations and grant-funded biopharmaceutical programs (including Gates Foundation and CEPI-funded initiatives), executed a non-exclusive CRISPR/Cas9 license with ERS Genomics, rebranded as Dyadic Applied BioSolutions, and announced a March 25, 2026 earnings conference call.

Filing Facts

CIK

1213809

Ticker

-

Form

8K

Source Type

sec

Accession

0001493152-26-012673

Alert Tier

6